Timeline of antibiotics
From Timelines
This is a timeline of antibiotics, also known as antibacterials and antimicrobials.
Contents
Big picture
Time period | Development summary |
---|---|
<19th century | although people did not know infections were caused by bacteria, antibiotics have been used for millennia to treat infections. Some of the earliest civilizations used various moulds and plant extracts to treat infections. The ancient Egyptians, for example, applied mouldy bread to infected wounds.[1] |
19th century | Scientists begin to observe antibacterial chemicals in action.[1] By the late century, a few notable breakthroughs occur. |
20th century | Antibiotics revolutionized medicine during the later half of the 20th century.[2] The major event in the history of antibiotics is the discovery of penicillin by Alexander Fleming in 1928. The first antibiotics are prescribed in the late 1930s.[3] The period between the 1950s and 1970s is considered the golden era of discovery of novel antibiotics classes, with no new classes discovered since then.[4] In fact, between 1944 and 1972 human life expectancy jumped by eight years, largely due to the introduction of antibiotics.[3] In the 1970s and 1980s synthetic versions of erythromycin, including clarithromycin and azithromycin, are developed.[5] After the 1970s, with the decline of the discovery rate, the mainstream approach for the development of new drugs to combat emerging and re-emerging resistance of pathogens to antibiotics would be the modification of existing antibiotics.[4] In the 1980s and 1990s, scientists only manage to make improvements within classes.[6] |
Full timeline
Note: The event type "introduction" could mean the discovery of the drug, its approval for use or its commercial release.
Year | Event type | Details | Geographical location |
---|---|---|---|
350 CE–550 CE | Traces of tetracycline are found in human skeletal remains from ancient Sudanese Nubia.[4][2] | ||
1877 | French microbiologist Louis Pasteur shows that the bacterial disease anthrax, can be rendered harmless in animals with the injection of soil bacteria. | ||
1887 | German bacteriologist Rudolf Emmerich shows that the intestinal infection cholera is prevented in animals that have been previously infected with the streptococcus bacterium and then injected with the cholera bacillus. | ||
1888 | German scientist E. de Freudenreich manages to isolate an actual product from a bacterium that had antibacterial properties.[7] | ||
1896 | French medical student Ernest Duchesne originally discovers the antibiotic properties of Penicillium.[8][9][10] | ||
1907 | German chemist Alfred Bertheim and Paul Ehrlich discover arsenic-derived synthetic antibiotics. This marks the beginning of the era of antibacterial treatment.[11] | ||
1909 | German physician Paul Ehrlich discovers that a chemical called arsphenamine is an effective treatment for syphilis.[1] | ||
1912 | Introduction | Paul Ehrlich discovers Neosalvarsan, a synthetic chemotherapeutic.[12] | |
1928 | Introduction | Scottish microbiologist Alexander Fleming, a Professor of Bacteriology at St Mary’s Hospital in London, discovers penicillin after sorting through some petri dishes containing a bacteria called staphylococcus, which causes boils, sore throats and abscesses. Flemming discovers killed baceria in one dish contaning a blob of mold on it.[7][5] | United Kingdom |
1930 | French-born American microbiologist René Dubos isolates from a soil microorganism an enzyme that can decompose part of the bacillum that causes lobar pneumonia in humans.[13] | ||
1932 | German pathologist Gerhard Domagk develops prontosil, the first sulphonamide microbial.[14][15][16] | Germany | |
1936 | Introduction | w:Sulfonamide (medicine)Sulfonamide antibacterial Sulfanilamide is introduced.[17] | |
1937 | The first effective antimicrobials (sulfonamides) are introduced.[18] | ||
1938 | Sulfapyridine is introduced.[19] | ||
1939 | Microbiologist René Dubos manages to isolate an antibacterial substance and names it tyrothricin.[13] | ||
1939 | Introduction | Gramicidin is discovered. | |
1939 | "1939, that Howard Florey, Ernst Chain, and Norman Heatley" | ||
1939 | Introduction | sulfonamide antibiotic sulfacetamide is introduced.[20] | |
1940 | Introduction | Sulfonamide antibiotic sulfamethizole is introduced.[21][22][23] | |
1941 | Introduction | β-lactam antibiotics are introduced.[24] | |
1941 | Introduction | Penicillin is introduced for medical use.[25][16] Just before the introduction of penicillin, the mortality rate from Staphylococcus aureus infections that had reached the blood stream was reported to be 80%.[25] | |
1942 | Ernst Chain, Howard Florey and Edward Abraham succeed in purifying the first penicillin, penicillin G. | ||
1942 | Introduction | Sulfadimidine is introduced as a single compound.[26][27][28] | |
1942 | Resistance | Penicillin resistant bacteria are first detected, about one year after the introduction of penicillin.[25] | |
1942 | Introduction | Gramicidin S, the first peptide antibiotic, is isolated by Gauze and Brazhnikova.[29][30][31] | |
1943 | Introduction | American biochemists Selman Waksman, Albert Schatz, and Elizabeth Bugie discover antibiotic streptomycin, the first aminoglycoside. It is the first antibiotic effective against tuberculosis.[5][32][33][34][16] | United States |
1943 | Introduction | Sulfamerazine is introduced.[35][36][37] | |
1943 | Production | Penicillin is mass produced and used heavily to treat Allied troops fighting in Europe during World War II.[2] | |
1943 | Introduction | Bacitracin is discovered.[38] | |
1945 | Introduction | The cephalosporins are discovered from a fungus, Cephalosporium acremonium, in seawater samples near a sewage outfall in Sardinia.[16][39][40][41] | Italy |
1947 | Introduction | Chloramphenicol is isolated from the soil organism Streptomyces venezuelae. Merketed in 1949, its use would quickly become widespread due to its broad spectrum of antimicrobial activity.[42][43][44][45] | |
1947 | Scientific development | American plant physiologist Benjamin Minge Duggar isolates chlortetracycline from a Missouri River mud sample. It is the first tetracycline introduced.[46][47][48][49] | United States |
1947 | Introduction | Antibiotic polymyxin family of antibiotics is discovered, with polymyxin B being the first isolated from bavterium paenibacillus polymyxa.[5][50][51] | |
1947 | Introduction | Nitrofuran is introduced.[24] | |
1949 | Jewish-American biochemist Selman Waksman and Hubert A. Lechevalier first isolate neomycin, as aminoglycoside antibiotic found in many topical medications such as creams, ointments, and eyedrops.[52][53][54] | United States | |
1949 | Scientific development | British chemist Dorothy Hodgkin reveals the complete structure of molecular penicillin, using the X-ray crystallography.[18] | United Kingdom |
1950 | Introduction | Oxytetracycline comes into commercial use.[38][55][56] | |
1950 | Resistance | Resistance against chloramphenicol is observed.[57] | |
1952 | Introduction | Macrolides are introduced.[24] | |
1952 | Introduction | Lincosamides are introduced.[24] | |
1952 | Introduction | Eli Lilly and Company introduces erythromycin, an antibiotic useful for the treatment of a number of bacterial infections, including respiratory tract infections, skin infections, chlamydia infections, pelvic inflammatory disease, and syphilis.[58][59][60] | United States |
1952 | Introduction | Streptoramins are introduced.[24] | |
1953 | Introduction | Oxford University scientists discover antibiotic cephalosporin C.[5] | United Kingdom |
1953 | Resistance | Macrolide resistance is observed.[24] | |
1954 | Introduction | Benzathine penicillin is established as a method for the treatment of syphilis.[61] | |
1956 | Introduction | Research team at the Lilly Biological Laboratories in Indiana first isolates vancomycin from bacterium streplomyces orienlalis. Vancomycin is used as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant staphylococcus aureus.[16][62][63][64] | United States |
1956 | Introduction | Glycopeptides are introduced.[24] | |
1956 | Resistance | Resistance against erythromycin is observed.[57] | |
1957 | Introduction | Kanamycin is discovered.[38] | |
1957 | Introduction | Ansamycins are introduced.[24] | |
1959 | Introduction | Colistin becomes available for treating infections caused by gram-negative bacteria.[5] | |
1959 | Introduction | Nitroimidazoles are introduced.[24] | |
1960 | Introduction | In an attempt to defeat penicillin-resistant strains, scientists develop methicillin, a different antibiotic in the penicillin class.[2][57] | |
1961 | Resistance | Methicillin resistance is first reported.[25][57][24] | |
1961 | Introduction | Antibiotic ampicillin is introduced. Within a short time it would become the drug of choice for treatment of Hemophilus influenzae meningitis.[65][66][67][16] | |
1961 | Resistance | Methicillin-resistant staphylococcus aureus is first reported in the United Kingdom, just a year after the antibiotic methicillin was introduced in the country.[5] | |
1961 | Introduction | Spectinomycin is first reported.[38] | |
1962 | Introduction | Quinolones are discovered accidentally, as a byproduct of some research on the antimalarial drug chloroquine.[5][24] | |
1963 | Introduction | Weinstein and his colleagues from the Schering Corporation describe the first isolation of the gentamicin complex.[16][68][69][70] | United States |
1963 | Introduction | Gentmicin is discovered.[38] | |
1963 | Resistance | Gram-negative bacterium acinetobacter baumannii becomes an antibiotic resistant pathogen.[25] | |
1965 | Dicloxacillin is synthesized by Bayer.[71][72][73] | ||
1966 | Resistance | Nalidixic acid resistance is observed.[24] | |
1966 | Introduction | Antibiotic doxycycline is introduced.[74][75][76][16] | |
1966 | Resistance | Resistance against cephalotin is observed.[57] | |
1967 | Introduction | Clindamycin is first reported.[38] | |
1968 | Introduction | Antibiotic rifampicin is introduced for clinical use.[77][78][79] | Italy |
1968 | Resistance | Tetracycline resistance is observed.[24][24] | |
1968 | Introduction | Trimethoprim is introduced.[24] | |
1970 | Introduction | Non-toxic semi-synthetic acid-resistant isoxazolyl penicillin flucloxacillin is introduced into clinical practice.[73][80] | |
1971 | Introduction | Tobramycin is discovered.[38] | |
1972 | Introduction | Cephamycins are discovered.[38] | |
1972 | Introduction | Antibiotic minocycline is discovered.[74][75][76] | |
1973 | Introduction | Carbenicillin is discovered.[81] | |
1974 | Introduction | Antibiotic trimethoprim/sulfamethoxazole is commercially released.[82][16] | |
1974 | Cotrimoxazole is introduced.[38] | ||
1976 | Introduction | Antibiotic amikacin is introduced.[16] | |
1976 | Resistance | Tufts University researcher Stuart B. Levy becomes one of the first to identify antibiotic resistance due to their use in animals.[2] | |
1976 | Introduction | Amikacin is introduced.[38] | |
1978 | Introduction | Cefoxitin is introduced.[81][83] | |
1981 | Resistance | AmpC beta-lactamase resistance is observed.[24] | |
1983 | Resistance | Extended-spectrum-beta-lactamase resistance is observed.[24] | |
1984 | Introduction | Antibiotic ampicillin/clavulanate is introduced.[16] | |
1984 | Introduction | amoxicillin clavulanate is introduced.[38] | |
1985 | Introduction | Researchers at Eli Lilly and Company discover antibiotic daptomycin.[84][85][86] | United States |
1985 | Introduction | Carbapenems are introduced.[57] | |
1986 | Resistance | Vancomycin-resistant enterococcus is reported.[57][24] | |
1987 | Introduction | Antibiotic imipenem/cilastin is introduced.[16] | |
1987 | Introduction | Highly potent fluoroquinolones are introduced.[18] | |
1987 | Introduction | Antibiotic ciprofloxacin is introduced.[16][87][88] | |
1987 | Resistance | Resistance against cephalosporins is observed.[57] | |
1987 | Resistance | Resistance against carbapenems is observed.[57] | |
1990s | Resistance | Fluorochinolone resistance is observed.[24] | |
1993 | Introduction | Antibiotics azithromycin and clarithromycin are introduced.[16] | |
1997 | Resistance | Vancomycin-resistant staphyloccocus is reported.[24] | |
1999 | Introduction | Antibiotic quinupristin/dalfopristin is introduced.[16] | |
2000 | Introduction | Oxazolidinones are introduced.[24] | |
2000s | Resistance | Resistance against linezolid and daptomycin is observed.[24] | |
2000 | Introduction | Antibiotic linezolid is introduced.[16][57] | |
2001 | Introduction | Antibiotic telithromycin is introduced in the European Union.[89][90][91] | |
2001 | Introduction | Broader-spectrum fluoroquinolones are introduced.[81] | |
2002 | Resistance | Resistance against linezolid is observed.[57] | |
2002 | Introduction | Cefditoren is introduced.[38] | |
2002 | Resistance | Vancomycin-resistant staphylococcus aureus is reported.[24] | |
2003 | Introduction | Lipopeptides are introduced.[24] | |
2003 | Introduction | Antibiotic daptomycin is introduced.[16] | |
2004 | Introduction | Telythromicin is introduced.[38] | |
2005 | Introduction | Antibiotic tigecycline is introduced for the treatment of skin and skin structure infections and intraabdominal infections.[92][93][94] | |
2010 | Publication | Authors of a report on the evolution of resistance note that microbes have “extraordinary genetic capabilities” that benefit “from man’s overuse of antibiotics to exploit every source of resistance genes... to develop [resistance] for each and every antibiotic introduced into practice clinically, agriculturally, or otherwise.”[2] | |
2012 | Study | A team of scientists propose adding the terms extensively drug-resistant (XDR) and pandrug-resistant (PDR) to multidrug-resistant (MDR) bacteria to better help them classify and potentially defeat superbugs.[2] | |
2014 | The World Health Organization (WHO) releases a statement in response to major superbug outbreaks like lebsiella pneumoniae (which causes pneumonia and bloodstream infections in the hospital) and gonorrhea strains all over the world, noting that “this serious threat is no longer a prediction for the future, it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country.”[2] | ||
2015 | Policy | American fast food company McDonald's announces that it would phase out all meat sources that contain antibiotics.[2] |
Meta information on the timeline
How the timeline was built
The initial version of the timeline was written by User:Sebastian.
Funding information for this timeline is available.
Feedback and comments
Feedback for the timeline can be provided at the following places:
- FIXME
What the timeline is still missing
Timeline update strategy
See also
External links
References
- ↑ 1.0 1.1 1.2 "THE HISTORY OF ANTIBIOTICS". microbiologysociety.org. Retrieved 29 March 2018.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "A Brief History Of Antibiotic Resistance: How A Medical Miracle Turned Into The Biggest Public Health Danger Of Our Time". medicaldaily.com. Retrieved 29 March 2018.
- ↑ 3.0 3.1 "antibiotics 1928-2000". abc.net.au. Retrieved 31 March 2018.
- ↑ 4.0 4.1 4.2 Aminov, Rustam I. "A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future". PMC 3109405. PMID 21687759. doi:10.3389/fmicb.2010.00134.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 "Ten important moments in the history of antibiotic discovery". correctiv.org. Retrieved 29 March 2018.
- ↑ "A brief history of antibiotics". news.bbc.co.uk. Retrieved 30 March 2018.
- ↑ 7.0 7.1 Newell-McGloughlin, Martina; Re, Edward. The Evolution of Biotechnology: From Natufians to Nanotechnology.
- ↑ Zhang, Yawei. Encyclopedia of Global Health, Volume 1.
- ↑ Myers, Richard L. The 100 Most Important Chemical Compounds: A Reference Guide.
- ↑ Manning, Shannon D.; Alcamo, I. Edward; Heymann, David L. Escherichia Coli Infections.
- ↑ SWATHY, S; ARYA, US. "ANTIBIOTIC USAGE IN PEDIATRICS" (PDF). INTERNATIONAL JOURNAL FOR INNOVATIVE RESEARCH IN MULTIDISCIPLINARY FIELD.
- ↑ "Neosalvarsan". sciencedirect.com. Retrieved 1 April 2018.
- ↑ 13.0 13.1 "René Dubos". britannica.com. Retrieved 30 March 2018.
- ↑ Ravina, Enrique. The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs.
- ↑ Savona-Ventura, Charles. Contemporary Medicine in Malta [1798-1979].
- ↑ 16.00 16.01 16.02 16.03 16.04 16.05 16.06 16.07 16.08 16.09 16.10 16.11 16.12 16.13 16.14 16.15 16.16 Torok, Estee; Moran, Ed; Cooke, Fiona. Oxford Handbook of Infectious Diseases and Microbiology.
- ↑ HUGHES, RAYMOND P. "THE USE OF SULFANILAMIDE IN DERMATOLOGY". doi:10.1001/archderm.1940.01490130037006.
- ↑ 18.0 18.1 18.2 Davies, Julian; Davies, Dorothy. "Origins and Evolution of Antibiotic Resistance" (PDF). doi:10.1128/MMBR.00016-10.
- ↑ "Clinical Pharmacokinetics of Sulfonamides and Their Metabolites". karger.com. Retrieved 1 April 2018.
- ↑ DUEMLING, WERNER W. "SODIUM SULFACETAMIDE IN TOPICAL THERAPY". doi:10.1001/archderm.1954.01540130077007.
- ↑ Vree, T.B. "Clinical Pharmacokinetics of Sulfonamides and Their Metabolites". doi:10.1159/000414195.
- ↑ Vree, Tom B.; Aaron, Yechiel; Karger, Hekster S. Antibiotics and Chemotherapy, Volume 37.
- ↑ The New Yorker, Volume 45, Part 2.
- ↑ 24.00 24.01 24.02 24.03 24.04 24.05 24.06 24.07 24.08 24.09 24.10 24.11 24.12 24.13 24.14 24.15 24.16 24.17 24.18 24.19 24.20 24.21 24.22 24.23 "Antibiotics armageddon?". mega.online. Retrieved 31 March 2018.
- ↑ 25.0 25.1 25.2 25.3 25.4 Landecker, Hannah. "Antibiotic Resistance and the Biology of History".
- ↑ "Clinical Pharmacokinetics of Sulfonamides and Their Metabolites". karger.com. Retrieved 1 April 2018.
- ↑ [Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments / Pharmaceuticals ] ; Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments. Pharmaceuticals. United Nations.
- ↑ Vree, Tom B.; Hekster, Yechiel Aaron. Antibiotics and Chemotherapy, Volume 37.
- ↑ Berditsch, Marina; Afonin, Sergii; Ulrich, Anne S. "The Ability of Aneurinibacillus migulanus (Bacillus brevis) To Produce the Antibiotic Gramicidin S Is Correlated with Phenotype Variation▿".
- ↑ GAUSE, G. F.; BRAZHNIKOVA, M. G. "Gramicidin S and its use in the Treatment of Infected Wounds". Nature. doi:10.1038/154703a0.
- ↑ Korzybski, Tadeusz; Kowszyk-Gindifer, Zuzanna; Kurylowicz, Wlodzimierz. Antibiotics: Origin, Nature and Properties.
- ↑ Lorian, Victor. Antibiotics in Laboratory Medicine.
- ↑ Morabia, Alfredo. Enigmas of Health and Disease: How Epidemiology Helps Unravel Scientific Mysteries.
- ↑ Cumo, Christopher Martin. The Ongoing Columbian Exchange: Stories of Biological and Economic Transfer in World History: Stories of Biological and Economic Transfer in World History.
- ↑ Santo Tomas Journal of Medicine, Volume 3. University of Santo Tomas, College of Medicine.
- ↑ Biennial Report. North Dakota. State Dept. of Health.
- ↑ Nelson loose-leaf living medicine, Volume 8. T. Nelson & Sons.
- ↑ 38.00 38.01 38.02 38.03 38.04 38.05 38.06 38.07 38.08 38.09 38.10 38.11 38.12 "The Golden Age of Antibacterials". amrls.cvm.msu.edu. Retrieved 31 March 2018.
- ↑ Stephanie Watts; Faingold, Carl; Dunaway, George; Crespo, Lynn. Brody's Human Pharmacology - E-Book.
- ↑ Riviere, Jim E.; Papich, Mark G. Veterinary Pharmacology and Therapeutics.
- ↑ Bennett, Peter N.; Brown, Morris J. Clinical Pharmacology E-Book: With STUDENTCONSULT Access.
- ↑ Kacew, Sam. Drug Toxicity and Metabolism in Pediatrics.
- ↑ Riviere, Jim E.; Papich, Mark G. Veterinary Pharmacology and Therapeutics.
- ↑ Shapiro, Stuart. Regulation of Secondary Metabolism in Actinomycetes.
- ↑ Aschenbrenner, Diane S.; Venable, Samantha J. Drug Therapy in Nursing.
- ↑ Dougherty, Thomas J.; Pucci, Michael J. Antibiotic Discovery and Development.
- ↑ Kokate, Chandrakant; Jalalpure, SS; Pramod, H.J. Textbook of Pharmaceutical Biotechnology - E-Book.
- ↑ Advances in Pharmacology and Chemotherapy.
- ↑ McKenna, John. Natural Alternatives to Antibiotics – Revised and Updated: How to treat infections without antibiotics.
- ↑ Antimicrobial Cationic Peptides—Advances in Research and Application: 2013 Edition: ScholarlyBrief.
- ↑ Annual Reports in Medicinal Chemistry, Volume 46. Academic Press, Oct 12, 2011 - Science.
- ↑ Schindel, Leo. Unexpected Reactions to Modern Therapeutics: Antibiotics.
- ↑ Grayson, M Lindsay; Crowe, Suzanne M; McCarthy, James S; Mills, John; Mouton, Johan W; Norrby, S Ragnar; Paterson, David L; Pfaller, Michael A. Kucers' The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs.
- ↑ Advances in Carbohydrate Chemistry, Volume 18.
- ↑ "CHEBI:27701 - oxytetracycline". ebi.ac.uk. Retrieved 2 April 2018.
- ↑ Shwachman, Harry; Schuster, Augusto. "The Tetracyclines: Applied Pharmacology".
- ↑ 57.00 57.01 57.02 57.03 57.04 57.05 57.06 57.07 57.08 57.09 57.10 Stearns, Stephen C.; Koella, Jacob C. Evolution in Health and Disease. Evolution in Health and Disease.
- ↑ Rubin, Bruce K.; Tamaoki, Jun. Antibiotics as Anti-Inflammatory and Immunomodulatory Agents.
- ↑ Piscitelli, Stephen C.; Rodvold, Keith A.; Pai, Manjunath P. Drug Interactions in Infectious Diseases.
- ↑ Nightingale; Mur. Antimicrobial Pharmacodynamics in Theory and Clinical Practice, Second Edition.
- ↑ Ellis, Albert; Abarbanel, Albert. The Encyclopædia of Sexual Behaviour, Volume 2.
- ↑ Staphylococci in Human Disease (Kent B. Crossley, Kimberly K. Jefferson, Gordon L. Archer, Vance G. Fowler ed.).
- ↑ Antibiotics Annual.
- ↑ Hejzlar, Miroslav. Advances in Antimicrobial and Antineoplastic Chemotherapy: Progress in Research and Clinical Application: pt. 1-2. Antimicrobial chemotherapy.
- ↑ Atta-ur-Rahman. Studies in Natural Products Chemistry, Volume 56.
- ↑ Thompson, R.A.; Green, John R. Infectious Diseases of the Central Nervous System.
- ↑ Fifty Years of Antimicrobials: Past Perspectives and Future Trends. Society for General Microbiology. Symposium.
- ↑ Advances in Applied Microbiology, Volume 18.
- ↑ Eardley, Ian; Whelan, Peter; Kirby, Roger; Schaeffer, Anthony. Drug Treatment in Urology.
- ↑ Antimicrobials: Synthetic and Natural Compounds (Dharumadurai Dhanasekaran, Nooruddin Thajuddin, A. Panneerselvam ed.).
- ↑ McGuire, John L. Pharmaceuticals, 4 Volume Set.
- ↑ Kuemmerle, Helmut Paul. Clinical Chemotherapy: Antimicrobial Chemotherapy.
- ↑ 73.0 73.1 Harper, N. J.; Simmonds, Alma B. Advances in Drug Research, Volume 7.
- ↑ 74.0 74.1 Yaffe, Sumner J.; Aranda, Jacob V. Neonatal and Pediatric Pharmacology: Therapeutic Principles in Practice.
- ↑ 75.0 75.1 Denyer, Stephen P.; Hodges, Norman A.; Gorman, Sean P.; Gilmore, Brendan F. Hugo and Russell's Pharmaceutical Microbiology.
- ↑ 76.0 76.1 Dirnagl, Ulrich; Elger, Bernd. Neuroinflammation in Stroke.
- ↑ Rahman, Atta -ur-; Choudhary, M. Iqbal. Frontiers in Anti-Infective Drug Discovery, Volume 6.
- ↑ Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set (y M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson ed.).
- ↑ Mann, R.D. Modern Drug use: An Enquiry on Historical Principles.
- ↑ Neonatal Formulary. BMJ Books, 2000.
- ↑ 81.0 81.1 81.2 "ANTIBIOTIC-TIMELINE". amrls.cvm.msu.edu. Retrieved 1 April 2018.
- ↑ "Pharmaceutical Marketing in India". books.google.com.ar. Retrieved 28 March 2018.
- ↑ Sandford Goodman,, Louis; Goodman Gilman, Alfred. Goodman and Gilman's: The Pharmacological Basis of Therapeutics.
- ↑ Current Medical Research and Opinion, Volume 22, Issues 9-12. Clayton-Wray Publications Limited, 2006.
- ↑ Rybak, M. J. "The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram‐positive bacteria".
- ↑ Beiras-Fernandez, Andres; Ferdinand Vogt, Ferdinand Vogt; Sodian, Ralf; Weis, Florian. "Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens". PMC 3108743. PMID 21694898. doi:10.2147/IDR.S6961.
- ↑ Andriole, Vincent T. The Quinolones.
- ↑ Aronson, Jeffrey K. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions.
- ↑ Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set (M. Lindsay Grayson, Sara E. Cosgrove, Suzanne Crowe, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson ed.).
- ↑ Alex, Alexander; Harris, C. John; Smith, Dennis A. Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward.
- ↑ Hugo and Russell's Pharmaceutical Microbiology (Stephen P. Denyer, Norman A. Hodges, Sean P. Gorman, Brendan F. Gilmore ed.).
- ↑ Low-dose antibiotics: current status and outlook for the future (Robert Paul Hunter, Carlos F Amábile-Cuevas, Jun Lin, Joshua D Nosanchuk, Rustam Aminov ed.).
- ↑ Vincent, Jean-Louis; Abraham, Edward; Kochanek, Patrick; Moore, Frederick A.; Fink, Mitchell P. Textbook of Critical Care E-Book.
- ↑ Trauma: Critical Care (William C. Wilson, Christopher M. Grande, David B. Hoyt ed.).